EirGenix

TPEx: 6589

YOUR RELIABLE BIOLOGICS PARTNER

Cathay Securities Healthcare Corporate Day
Aug 16, 2022

Dr. Chih-Jung Chang
Vice President, COO

DISCLAIMER

This material has been prepared by EirGenix, Inc. (“EirGenix”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. EirGenix is under no obligation to update or keep current the information contained herein. The information contained in this presentation is EirGenix’s confidential information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of EirGenix. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.

No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to, the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

EirGenix Profile and USPs

- Established Dec. 21, 2012
  - 2013/03 Completed acquisition of DCB's Biopharmaceutical Pilot Facility 財團法人生物技術開發中心 Development Center for Biotechnology
  - 2019/06 IPO on TPEx (Code: 6589.TWO) China Area Award
- Back up by very strong and stable investors include:
  - **Founder of Foxconn, Terry Gou**
  - **Government and pan-government investment funds**
  - **Formosa Laboratories**
- Dual business model : **CDMO Services** and **Own-Product Development (Biosimilars)**
- CDMO Achievements
  - 2018 Asia's Best Biologics CMO Award
  - 2019 BioProcessing Excellence in Taiwan Award
  - 2020 BioProcessing Excellence in Greater China Area Award
- **Rated 2021 Top 5% Corporate Governance Evaluation at TPEx after second year of the IPO**

EirGenix Office, Facilities & Business Partners



Recent Zhubei Facility Expansion Update

Zhubei - Building B (Microbial Production Line)
Currently under construction, expect to be ready by 2024-end for
1x 350L and,

1x 1000L
production lines

Zhubei- Building A (Mammalian Production Line)
Started production since 2019

5F: New production line to ready by 2023 Q1 for 3 sets 2x 2000L

3F: Original capacity

2 sets 2x 2000L
2022 Q3 will complete install additional 1 set 2x 2000L

Capacity and Expansion Schedule (Xizhi, Zhubei + New Site)

Mammalian cell culture capacity – 9,500 L (**25,500L by 2023 Q1**) | Microbial fermentation capacity – 150 L (**1,500L by 2024**)





- 2019/Q1 The first large scale mammalian commercial production in the Zhubei facility on stream
- 2022/Q3 Additional 2 sets of 2x2000L mammalian capacity expansion to complete. Totaled 13,500 L
- 2023/Q1 The 2nd mammalian cell culture production line to complete (3 sets of 2x2000L). Totaled 25,500 L
- A 6-8 years plan to build up a 150,000 L very large-scale mammalian cell culture facility in 3 stages (50 KL by 2025/26, 100 KL by 2028, and 150 KL by 2030). **Total mammalian capacity to reach 175,500L**

- 2024 Expansion of Zhubei facility Building "B" for microbial fermentation capacity (350 + 1000 L) with 2-3 downstream purification suites; **Total microbial fermentation capacity to reach 1,500 L by 2024**

Business Overview



Revenue Momentum

- 2022 Jan-Apr CDMO newly signed contracts exceed 60% of 2021 full-year contracts





Revenue Momentum (from EG12014 Licensing fee)

- Total licensing fee US$70mn (Upfront Payment US$5mn + Milestone US$65mn)

As of 2022/June



Included realized upfront payment and milestone payments realized based on R&D and clinical development

CDMO Projects & Stages (2020-2021)

- Mammalian & Microbial Dual Expression Systems
- Over 70 CDMO projects (2020-2021)
- 4 late-stage projects with near-term value
- Accelerated CDMO business momentum driven by cumulated experience



Global Compliance & Certifications

- EirGenix strongly believes in adherence to global standards and continually seeks to meet these standards year after year

65+

External audits/inspections by TFDA & clients throughout the world since 2005

YEAR	PREVIOUS CERTIFICATION OR INSPECTION
2005	**Mammalian** Cell culture production facility granted **GMP** certificate by **TFDA**
2013	**Microbial** production facility granted **GMP** certificate by **TFDA**
2014	Mammalian cell culture and microbial production facilities were certificated by TFDA as a **PIC/S GMP** facility
2017	Granted **Accreditation Certificate of Foreign Manufacturer** by Minister of Health, Labor and Welfare, **Japan**
2020	Granted approval by **Pharmaceuticals and Medical Devices Agency (PMDA), Japan**
2020	Zhubei facility passed the inspection by Taiwan FDA
2022	**Inspected by US FDA pending for inspection result**
2022-end/2023	**Expected inspection by EU EMA**

IO Biosimilars Potential

- The global market size of Immuno-Oncology products in 2021 is around $63 billions USD, and is expected to reach $93 billions USD at a CAGR of 10% in 2025
- It is believed that the growth rate has been hammered due to the treatment cost with IO drugs. Successfully early launch IO biosimilar products would immediately increase the volume of use though the price competition
- Potential development alliance to reduce the high development cost and the risks

Own Product Pipeline

Project Name	Drug Class	Indication	Target	PROGRESS				
				Pre-Clinical	Phase I	Phase II/III	MAA/BLA	Partner
EG12014 / EGI014 Trastuzumab Biosimilar	Monoclonal Antibody	Cancer	HER2					PARTNERED WITH SANDOZ A Novartis Division
EG1206A Pertuzumab Biosimilar	Monoclonal Antibody	Cancer	HER2					CURRENTLY CONFIDENTIAL
EG13074 TRZ (SC formulation)	Monoclonal Antibody	Cancer	HER2					CURRENTLY CONFIDENTIAL
EG12043 (TSY0110) Antibody Drug Conjugate	Antibody Drug Conjugate	Cancer	HER2					PARTNERED WITH FORMOSA LABORATORIES, INC.
EG13084 TRZ+PTZ (SC formulation)	Monoclonal Antibody	Cancer	HER2					
EG74032 CRM197 Carrier Protein	Carrier Protein for Vaccine Conjugates	N/A	Infectious /cancer					
EG62054 Biosimilar	Fusion Protein	Ophthalmology / Cancer	VEGF					

Why Her2 Family Products?

- Using the combination of trastuzumab + pertuzumab to treat Her 2 positive metastatic breast cancer (MBC) is a standard procedure, and it also becomes a trend to use the combination therapy for treating early breast cancer (EBC)
- The global market size of Her 2 positive breast cancer is around $13 billions USD
- To develop EirGenix's own pertuzumab (EG1206A) and be the top 2 to launch the product would have the complimentary effect to enhance the market penetration of EirGenix's trastuzumab (EG12014)
- EG has developed the proprietary high concentration SC formulations for trastuzumab. High concentration SC formulation of EG12014 + EG1206A is being developed. The successful development of high concentration SC formulation will further enhance EG's Her 2 family products penetration in the market, and it will help EG dominate the Her 2 biosimilar market

Self-Own Product Development Progress

Broad & diversified product pipeline; unique strategy of Her2 products franchise management

- The 1st own product, Herceptin Biosimilar EG12014 (Herwenda® - Sandoz | Eirguson® - EirGenix)
  - 2019/04 Signed global licensing (excluding Taiwan, Mainland China, Japan, S. Korea and Russia) agreement with **Sandoz AG (of the Novartis Group)** for the upfront and milestone payment of US$ 70 millions plus the profit sharing of the future sales
  - 2021/03 Global Phase III Clinical Trial met no clinically and meaningful differences standard
  - 2021/12 Submitted both BLA in US and MAA in EU almost at the same time
  - 2022/6 US FDA finished Zhubei facility inspection, pending for inspection results

  (Due to Covid-19 condition, EMA may follow FDA's results based on the mutual recognition agreement)
  - **Expect to receive marketing licensing approval by 2022-end/early-2023**

- The 2nd own product Pertuzumab Biosimilar EG1206A
  - 2022/Q1 Submitted Phase 1 clinical (German PEI & EC)
  - 2022/05 Received approval for Phase I PK bio-similarity clinical study from German National Competent Authority and corresponding Ethic Committee.

Reference Drug and Biosimilar Drug Market Share Change After Patent Expired

- Roche's Herceptin® as an example. Other substitute drug and biosimilar drugs penetrated over 75% of its market share within three years, after its patent expired since 2019.
- Early entry biosimilar drug received marketing license in US & EU + Strong global distribution channels to have the advantage of wining larger market share after reference drug patent expired.



Source: IQVIA

EirGenix's EG1206A is the Biosimilar drug of Roche's Perjeta

- Perjeta is Roche's another Her2+ monoclonal antibody drug for treating breast cancer
- Perjeta's 2021 sales revenue reached CHF 3.96bn (~US$ 4.2bn) and yet reaching sales peak
- Presuming biosimilar market value equivalent to 50% of the reference drug market value, which roughly ~US$2.1bn (based on Perjeta 2021 sales)
- Based on above assumptions, every 10% market penetration expect to contribution US$210mn sales revenue
- With additional combination therapy treatment using EG12014，likely to fuel sales momentum for EirGenix's EG12014



Future Product Pipeline Overview

Biosimilars

Her 2 Family

- EG12014
- EG1206A
- EG12043 (TSY0110)
- EG62054
- EGxxxxx
- EGxxxxx
- EGxxxxx
- EGxxxxx

New List to be:

1) **In-house developed**, or
2) **In-licensed**, or
3) **Potential IO biosimilars development alliance**

New Formulations & Drug Delivery for Biosimilars

Her 2 Family SC route

- EG13074
- EG13084

Specialty Biologics

- EG74032 CRM 197
- EG74091 HRV3C

Me-too/Novel (NCE)

- BDC-1001

* Immune Stimulating Antibody Conjugate (ISAC) - collaboration

Q & A

The health of the humankind and Client's Success is Our Priority

EirGenix

EirGenix, Inc.

台康生技股份有限公司